Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q7Z5Q5
UPID:
DPOLN_HUMAN
Alternative names:
-
Alternative UPACC:
Q7Z5Q5; A2A336; B4E158; Q4TTW4; Q6ZNF4
Background:
DNA polymerase nu, characterized by its low fidelity and unique ability to catalyze misincorporation during DNA synthesis, stands out in the DNA polymerase A family for its role in translesion DNA synthesis (TLS) and repair mechanisms. It efficiently bypasses DNA lesions, contributing to cellular tolerance to DNA damage without exonuclease activity.
Therapeutic significance:
Understanding the role of DNA polymerase nu could open doors to potential therapeutic strategies, particularly in enhancing the precision of DNA repair mechanisms and improving resistance to DNA-damaging agents.